N
CODX

Natixis’s Co-Diagnostics CODX Stock Holding History

Natixis’s Portfolio CODX Stock Details CODX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-467
Closed -$116K – 1209
2021
Q2 		$116K Buy
467
+100
+27% +$25.7K ﹤0.01% 827
2021
Q1 		$105K Sell
367
-56
-13% -$22.4K ﹤0.01% 1038
2020
Q4 		$118K Sell
423
-224
-35% -$83K ﹤0.01% 1012
2020
Q3 		$264K Buy
+647
New +$332K ﹤0.01% 673

Other funds holding CODX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PPA
Parametric Portfolio Associates Seattle, Washington $190B AUM 18.52% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
ARC
Advisor Resource Council Dallas, Texas $309M AUM 22.32% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Natixis's CODX Position: Q3 2021 in Review

Natixis sold out of Co-Diagnostics (CODX) in Q3 2021, closing a stake of 467 shares — an estimated $116K sold.

Natixis first reported a position in CODX in Q3 2020 and held it in 4 quarters. The position peaked at $264K in Q3 2020. 78 funds tracked by Wall St. Rank hold CODX as of Q3 2021.

  • Natixis reported no remaining Co-Diagnostics position as of Q3 2021 after selling out during the quarter.
  • Natixis sold 467 Co-Diagnostics shares in Q3 2021, an estimated $116K.
  • Natixis first reported a position in Co-Diagnostics in Q3 2020 and held it in 4 quarters.
  • Natixis's Co-Diagnostics position peaked at $264K in Q3 2020.
  • 78 funds tracked by Wall St. Rank held Co-Diagnostics as of Q3 2021.

Based on Natixis's 13F filing for Q3 2021, filed 12 Nov 2021.